Disease Domain | Count |
---|---|
Neoplasms | 3 |
Nervous System Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Proteolysis-targeting chimeras (PROTAC) | 2 |
Target |
Mechanism PI3Kγ inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
WO2024110592 ( CRAC x RYR1 x RyR )Patent Mining | Nervous System Diseases More | Discovery |
US20220304965 ( GABBR1 )Patent Mining | Digestive System Disorders More | Discovery |
BIM2b ( L-lactate dehydrogenase ) | Glioblastoma More | Discovery |
US20240252658 ( PXR )Patent Mining | Neoplasms More | Discovery |
WO2025087879 ( Akt x PI3Kγ x PIK3R5 )Patent Mining | Neoplasms More | Discovery |